CSPCY:OTCMKTS
CSPC Pharmaceuticals Group ADR
5,03 US$
0,00%
(0,00) 1D
6 tet, 3:39:35 m.d., GMT-4 · USD
search
Të gjitha simbolet
| Me simbole | Çmimi | Ndrysho | % ndryshim |
|---|
insights_autoPo gjenerohen statistikat kryesore për CSPCY...
Kapitalizimi i tregut
108,16 mld
Vëllimi mesatar
1,61 mijë
Vëllimi
0,00
Maksimumi 52-javor
5,46 US$
Minimumi 52-javor
3,26 US$
Beta
0,37
Aksionet në qarkullim
2,88 mld
Numri i punonjësve
19 mijë
Kapitalizimi i tregut
108,16 mld
Vëllimi mesatar
1,61 mijë
Vëllimi
0,00
Maksimumi 52-javor
5,46 US$
Minimumi 52-javor
3,26 US$
Beta
0,37
Aksionet në qarkullim
2,88 mld
Numri i punonjësve
19 mijë
Lajmet
Nga burimet në ueb dhe partnerët e lajmeve
AD HOC NEWS
·
1 ditë më parë
CSPC Pharma stock falls 1.15 percent ahead of ESMO data
TipRanks
·
2 ditë më parë
CSPC to Showcase Breakthrough HER2 Oncology Data at ESMO 2026
Profili
CSPC Pharmaceutical Group researches, develops, manufactures and sells pharmaceutical products. Its headquarters is in China's Hebei Province.
CSPC produces both active pharmaceutical ingredient and formulations. API products include
penicillin, cefalosporins, synthetic vitamins, caffeine and ranitidine. Formulations include antibiotics, butylphthalide and analgesics, in addition to nearly 1,000 other products.
CSPC's 15,000 employees are divided among more than ten subsidiaries, including CSPC Zhongrun, Weisheng, Zhongnuo and NBP.
CSPC Pharma's total assets are valued above RMB 8 billion. In 2007, CSPC Pharma achieved sales of RMB 8 billion and net income of RMB 485 million. Direct exports of US$300 million ranked CSPC first among China's pharmaceutical enterprises.
One subsidiary, China Pharmaceutical Group Co., Ltd is based in Hong Kong. It is listed on the Hang Seng China-Affiliated Corporations Index. In 2003 and 2004, China Pharma was listed as one of 100 excellent listed companies with turnover less than $1 billion.
CSPC Pharma is recognized as one of China's "500 Most Valuable Chinese Brands" and "Top 500 Chinese Enterprises." Wikipedia
Rreth CSPC Pharmaceuticals Group ADR